Journal: Alzheimer's Research & Therapy

Article Title: Photobiomodulation mitigates blood–brain barrier disruption in APP/PS1 mouse model of Alzheimer’s disease by activating the AMPK pathway

doi: 10.1186/s13195-025-01787-7

Figure Lengend Snippet: PBM Promotes the Transport Clearance of Aβ Deposition by the BBB in APP/PS1 Mice. A Western blot analysis of Aβ and LRP1 expression in mouse hippocampa tissue along with quantitative assessment. B Immunofluorescence staining in mouse cortex using anti-CD31 (green) and anti-LRP1 (red) antibodies (Scale bar: 50 μm). C Immunohistochemical staining for Aβ in the hippocampal region of mice (Scale bar: 100 μm). Arrows indicate Aβ deposition. D Immunofluorescence staining in the hippocampal region of mice using anti-Aβ (red) and anti-IBA1 (green) antibodies (scale bars: 200 μm and 20 μm, respectively). E Immunofluorescence staining in the hippocampal region of mice using anti-Aβ (red) and anti-GFAP (green) antibodies (scale bars: 200 μm and 50 μm, respectively). Data are presented as Mean ± SEM ( n = 3 per group). Comparisons indicate statistical significance relative to the Control group: ** p < 0.01, *** p < 0.001 and relative to the AD group: # p < 0.05

Article Snippet: LRP1 Antibody , Wuhan Boster (BM4098) , 1:200.

Techniques: Western Blot, Expressing, Immunofluorescence, Staining, Immunohistochemical staining, Control

Journal: Alzheimer's Research & Therapy

Article Title: Photobiomodulation mitigates blood–brain barrier disruption in APP/PS1 mouse model of Alzheimer’s disease by activating the AMPK pathway

doi: 10.1186/s13195-025-01787-7

Figure Lengend Snippet: PBM Improves Inflammation-induced TJs Damage in bEnd.3 Cells. A Schematic illustration of the Transwell BBB model and the optical parameters used for 808 nm laser irradiation. B FLU assay to evaluate the permeability of the monolayer bEnd.3 BBB model. C-E Immunofluorescence staining of bEnd.3 cells showing the expression of the TJs protein ZO-1 (red) and DAPI (blue), as well as LRP1 (red) with DAPI (blue), including quantitative analysis (Scale bar: 100 μm). F-I RT-PCR analysis of mRNA expression for TJs proteins Occludin, Claudin-5, ZO-1 and LRP1. J RT-PCR assessment of MMP-9 mRNA expression. K ELISA analysis of MMP-9 secretion in the supernatant of bEnd.3 cells. Data are presented as Mean ± SEM ( n = 3 per group). Comparisons indicate statistical significance relative to the Control group: * p < 0.05, ** p < 0.01, *** p < 0.001 and relative to the LPS group: # p < 0.05, ## p < 0.01, ### p < 0.001

Article Snippet: LRP1 Antibody , Wuhan Boster (BM4098) , 1:200.

Techniques: Irradiation, Permeability, Immunofluorescence, Staining, Expressing, Reverse Transcription Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Control

Journal: Alzheimer's Research & Therapy

Article Title: Photobiomodulation mitigates blood–brain barrier disruption in APP/PS1 mouse model of Alzheimer’s disease by activating the AMPK pathway

doi: 10.1186/s13195-025-01787-7

Figure Lengend Snippet: PBM Improves Inflammation-induced TJs Damage in bEnd.3 Cells by Activating AMPK. A Schematic diagram illustrating AMPK activation in bEnd.3 cells by PBM. B ELISA analysis of MMP-9 secretion in the supernatant of bEnd.3 cells following AICAR/Compound C treatment. C RT-PCR assessment of MMP-9 mRNA expression after treatment with AICAR/Compound C. D-E Immunofluorescence staining of the transport protein LRP1 (red) and DAPI (blue) in bEnd.3 cells following AICAR/Compound C treatment (Scale bar: 100 μm) with quantitative analysis. F–H RT-PCR analysis of Occludin, Claudin-5 and ZO-1 mRNA expression following AICAR/Compound C treatment. Data are presented as Mean ± SEM ( n = 3 per group). Comparisons indicate statistical significance relative to the Control + p-AMPK group: * p < 0.05, ** p < 0.01, *** p < 0.001 and relative to the Control + ko-AMPK group: # p < 0.05, ## p < 0.01, ### p < 0.001, relative to the p-AMPK group, ▲ p < 0.05, ▲▲ p < 0.01, ▲▲▲ p < 0.001

Article Snippet: LRP1 Antibody , Wuhan Boster (BM4098) , 1:200.

Techniques: Activation Assay, Enzyme-linked Immunosorbent Assay, Reverse Transcription Polymerase Chain Reaction, Expressing, Immunofluorescence, Staining, Control

Journal: Journal of Biological Chemistry

Article Title: Insulin-regulated Glut4 Translocation

doi: 10.1074/jbc.m114.555714

Figure Lengend Snippet: FIGURE 5. Differentiation decreases cell surface LRP1/2-M receptor and 2-M uptake by decreasing kex in both basal and insulin-stimulated cells. 3T3-L1 fibroblasts (gray) or adipocytes (white) were incubated with or without 100 nM insulin for 30 min (circles, basal; squares, insulin). AF647-2-M was added(withorwithoutinsulin)forthetimesindicated,andthencellswereplacedoniceandanalyzedbyflowcytometry.TolabelsurfaceLRP1,additionalwells were incubated with AF647-2-M for 90 min at 4 °C. Data are the average of means S.D. (error bars) (A and C) or S.E. (error bars) (B and D) of n 4 (fibroblasts) or n 5 (adipocytes) independent experiments. A, surface/total LRP1, estimated by comparing the LRP1 surface binding to total labeling after chloroquine treatment (16). Fibroblasts: basal, 0.22 0.02; insulin, 0.24 0.02. Adipocytes: basal, 0.069 0.006; insulin, 0.11 0.01. Relative surface levels of LRP1 were verified by anti-LRP1 binding (data not shown). B, AF647-2-M uptake. Lines, linear fits of the data. C and D, endocytic rate constants (ken) were calculated from the slope of the IN/SUR versus time plots (28). Fibroblasts: basal, ken 0.41 0.05 min1; insulin, ken 0.41 0.03 min1. Adipocytes: basal, ken 0.28 0.02 min1; insulin, ken 0.34 0.05 min1. E, exocytic rate constants (kex) were estimated using the partition coefficient (16); kex (PMLRP1 ken)/(1 PMLRP1). Fibroblasts: basal, kex 0.10 min1; insulin, kex 0.11 min1. Adipocytes: basal, kex 0.021 min1; insulin, kex 0.043 min1. F, AF647-2-M uptake. Lines, simulations using the model, dynamic retention with Tf receptor recycling (Table 3 and supplemental Fig. 1F). *, p 0.01; **, p 0.001 fibroblasts versus adipocytes.

Article Snippet: Relative surface levels of 2-M binding/LRP1 receptor were verified in independent samples by labeling with biotin-conjugated anti-LRP1 antibody (clone 8G1, Fitzgerald Industries International), followed by AF647 streptavidin (Invitrogen).

Techniques: Incubation, Binding Assay, Labeling

Journal: Journal of Biological Chemistry

Article Title: Insulin-regulated Glut4 Translocation

doi: 10.1074/jbc.m114.555714

Figure Lengend Snippet: FIGURE 6. AS160 knockdown in adipocytes increases surface LRP1/2-M receptor and 2-M uptake by increasing kex in both basal and insulin- stimulated cells. Control adipocytes expressing a nonspecific shRNA (white) or AS160 knockdown adipocytes (black) were treated and analyzed as described in Fig. 5. Data are the average means S.D. (error bars) (A and C) or S.E. (error bars) (B) of n 7 independent experiments. A, surface/total LRP1. Control: basal, 0.06 0.005; insulin, 0.13 0.01. AS160 KD: basal, 0.10 0.009; insulin, 0.15 0.02. B, AF647-2-M uptake. Lines, linear fits of the data. C and D, endocytic rate constants (ken) were calculated from the slope of the IN/SUR versus time plots (28). Control: basal, ken 0.27 0.01 min1; insulin, ken 0.31 0.02 min1. AS160 KD: basal, ken 0.39 0.03 min1; insulin, ken 0.41 0.03 min1. E, estimated exocytic rate constants (kex). Control: basal, kex 0.017 min1; insulin, kex 0.046 min1. AS160 KD: basal, kex 0.043 min1; insulin, kex 0.072 min1. F, AF647-2-M uptake. Lines, simulations (Table 3 and supplemental Fig. 1F). *, p 0.01; **, p 0.001, control versus AS160 KD.

Article Snippet: Relative surface levels of 2-M binding/LRP1 receptor were verified in independent samples by labeling with biotin-conjugated anti-LRP1 antibody (clone 8G1, Fitzgerald Industries International), followed by AF647 streptavidin (Invitrogen).

Techniques: Knockdown, Control, Expressing, shRNA

Journal: BIOCELL

Article Title: Apatinib reduces liver cancer cell multidrug resistance by modulating NF-κB signaling pathway

doi: 10.32604/biocell.2024.052625

Figure Lengend Snippet: FIGURE 5. Apatinib downregulates the expression levels of MDR-related genes in tumor tissues (n = 3). (A, B) The expression levels of the MDR1/P-gp, MRP2, LRP, GST-pi, and Topo IIα analyzed by real-time PCR and Western blot. GAPDH was used as a loading control. (C) Immunohistochemical analyses of MDR1/P-gp, MRP2, LRP, GST-pi, and Topo IIα in xenografts of nude mice. Original magnification, ×200 (scale bar, 50 μm). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Article Snippet: Tissue sections were incubated with primary antibodies (1:200 dilution, MRP2 (GeneTex, GTX130181, Irvine, CA, USA), P-gp (KA&M BIO, ANT(B)0337, Shanghai, China), GST-pi (Novatein Biosciences, Woburn, MA, USA), LRP (ProSci, PSI-15-516, Poway, CA, USA), Topo IIα (KA&M BIO, ANT (B)0092, Shanghai, China)) followed by an HRP-conjugated streptavidin-biotin complex (used at a dilution recommended by the kit, Thermo Scientific, E40970, Waltham, MA, USA).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Western Blot, Control, Immunohistochemical staining

Journal: European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery

Article Title: Plasma Low-density Lipoprotein Receptor-related Protein 1 Concentration is not Associated with Human Abdominal Aortic Aneurysm Presence.

doi: 10.1016/j.ejvs.2015.06.023

Figure Lengend Snippet: Figure 1. Plasma low-density lipoprotein receptor-related protein 1 (LRP1) is not associated with the presence of abdominal aortic aneurysm (AAA). (A) Enzyme-linked immunosorbent assay revealed no difference in circulating LRP1 concentrations in men with AAA (n ¼ 189) and nonaneurysmal controls (n ¼ 309; ManneWhitney U-test). B) No correlation was seen between plasma LRP1 concentration and infrarenal aortic diameter. Nonaneurysmal controls are boxed.

Article Snippet: The 60e250-kDa proteins were incubated with anti-LRP1 antibody (MAB6360; R&D Systems), while the proteins < 60 kDa were incubated with anti-b actin antibody (#AB75186; Abcam, Cambridge, UK) for 1 hour (room temperature).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Concentration Assay

Journal: European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery

Article Title: Plasma Low-density Lipoprotein Receptor-related Protein 1 Concentration is not Associated with Human Abdominal Aortic Aneurysm Presence.

doi: 10.1016/j.ejvs.2015.06.023

Figure Lengend Snippet: Figure 2. Western blot analysis of low-density lipoprotein receptor-related protein 1 (LRP1) expression in infrarenal aortic biopsies recovered from patients with abdominal aortic aneurysms (AAA) and nonaneurysmal organ donors. (A) Immunoblot detailing relative infrarenal aortic LRP1 expression in patients with AAA (AAA) and controls (CTRL). (B) Comparisons between groups revealed standardized aortic LRP1 expression to be significantly lower in patients with AAA than controls. Symbols represent individual samples; horizontal bars denote median and interquartile ranges. (C) Standardized LRP1 expression did not significantly correlate with infrarenal aortic diameter in the patients with AAA. Note. RDU ¼ relative density units.

Article Snippet: The 60e250-kDa proteins were incubated with anti-LRP1 antibody (MAB6360; R&D Systems), while the proteins < 60 kDa were incubated with anti-b actin antibody (#AB75186; Abcam, Cambridge, UK) for 1 hour (room temperature).

Techniques: Western Blot, Expressing